Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
about
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@en
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@nl
type
label
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@en
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@nl
prefLabel
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@en
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P1476
Phase 1 study of darolutamide ...... ion-resistant prostate cancer.
@en
P2093
Ako Hosono
Christian Zurth
Hirofumi Mukai
Kensei Hashizume
Mai Onomura
Masanobu Yasuda
Masaoki Sasaki
Miho Uemura
Nobuaki Matsubara
Yoko Yajima
P2860
P2888
P304
P356
10.1007/S00280-017-3417-3
P577
2017-08-11T00:00:00Z